[Form 4] Inmune Bio, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Inmune Bio, Inc. (INMB) reported that its Chief Executive Officer and director had multiple outstanding stock option awards repriced on November 18, 2025. Stockholders approved a one-time repricing of certain options granted under the company’s 2017, 2019, and Second Amended and Restated 2021 Stock Incentive Plans, reducing the exercise price of each affected option to $1.50, which was the company’s Nasdaq closing share price on the repricing date. For example, one stock option covering 400,000 shares originally exercisable at $7.80 was adjusted to a $1.50 exercise price. The filing states that all other terms of these repriced options, including vesting schedules and terms, remain unchanged, and exercisability continues to depend on the CEO’s ongoing service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moss David J

(Last) (First) (Middle)

C/O INMUNE BIO INC.

225 NE MIZNER BLVD., SUITE 640

(Street)

BOCA RATON FL 33432

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inmune Bio, Inc. [ INMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.8	11/18/2025		D(1)			400,000	(2)	01/01/2028	Common Stock	400,000	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		400,000		(2)	01/01/2028	Common Stock	400,000	(1)	400,000	D
Stock Option (right to buy)	$24.82	11/18/2025		D(1)			59,337	(2)	01/18/2031	Common Stock	59,337	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		59,337		(2)	01/18/2031	Common Stock	59,337	(1)	59,337	D
Stock Option (right to buy)	$3.91	11/18/2025		D(1)			275,000	(2)	11/24/2029	Common Stock	275,000	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		275,000		(2)	11/24/2029	Common Stock	275,000	(1)	275,000	D
Stock Option (right to buy)	$17.49	11/18/2025		D(1)			70,663	(2)	06/21/2031	Common Stock	70,663	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		70,663		(2)	06/21/2031	Common Stock	70,663	(1)	70,663	D
Stock Option (right to buy)	$9.74	11/18/2025		D(1)			160,000	(2)	02/15/2033	Common Stock	160,000	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		160,000		(2)	02/15/2033	Common Stock	160,000	(1)	160,000	D
Stock Option (right to buy)	$7.92	11/18/2025		D(1)			130,000	(2)	03/20/2032	Common Stock	130,000	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		130,000		(2)	03/20/2032	Common Stock	130,000	(1)	130,000	D
Stock Option (right to buy)	$5.05	11/18/2025		D(1)			223,000	(2)	12/04/2034	Common Stock	223,000	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		223,000		(2)	12/04/2034	Common Stock	223,000	(1)	223,000	D
Stock Option (right to buy)	$9.92	11/18/2025		D(1)			160,000	(2)	05/13/2034	Common Stock	160,000	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		160,000		(2)	05/13/2034	Common Stock	160,000	(1)	160,000	D

Explanation of Responses:

1. Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

2. This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

	/s/ David Moss	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Inmune Bio (INMB) disclose in this Form 4 filing?

Inmune Bio disclosed that its Chief Executive Officer and director had several existing stock option grants repriced, with their exercise prices reduced to $1.50 per share, effective November 18, 2025, following stockholder approval.

Whose compensation is affected in this Inmune Bio (INMB) Form 4?

The Form 4 relates to stock options held by the company’s Chief Executive Officer, who is also a director of Inmune Bio, Inc.

What is the new exercise price of the repriced Inmune Bio stock options?

The exercise price of each repriced stock option was reduced to $1.50 per share, which the filing states was the closing price of Inmune Bio’s common stock on The Nasdaq Capital Market on November 18, 2025.

Were vesting terms changed in Inmune Bio’s option repricing?

No. The filing states that, apart from the new $1.50 exercise price, all other terms and conditions of the repriced options, including vesting and term, remain in full force and effect.

Which stock incentive plans are involved in the Inmune Bio option repricing?

The repriced stock options were granted under Inmune Bio’s 2017 Stock Incentive Plan, 2019 Stock Incentive Plan, and Second Amended and Restated 2021 Stock Incentive Plan.

Can you give an example of a specific Inmune Bio option that was repriced?

One example in the filing is a stock option (right to buy) covering 400,000 shares of common stock that previously had a $7.80 exercise price and was adjusted to $1.50 per share as of November 18, 2025.

What condition applies to exercising the repriced Inmune Bio stock options?

The filing notes that the stock option awards become exercisable according to their vesting schedules and are subject to the reporting person’s continued service with Inmune Bio as of the applicable vesting dates.